PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Leukemia drug from Roche, AbbVie extends survival, study finds

A cancer drug from Roche and AbbVie, when combined with a commonly used chemotherapy, kept previously untreated patients with acute myeloid leukemia alive and in remission longer than chemo alone, the Swiss drugmaker said Monday.Patients in the Phase 3 trial, called VIALE-A, didn’t qualify for intensive chemotherapy treatment initially because of age or other medical conditions. The study should strengthen the case for use of Roche and AbbVie’s drug, Venclexta, in frontline disease, where it currently has only conditional approval.Last month, however, the companies revealed Venclexta failed in the VIALE-C trial, which tested the drug in a similar setting but paired it with another chemotherapy called cytarabine.

Winning accelerated approval isn’t usually the end of the story for drugs granted the designation by the Food and Drug Administration. In AML, Roche and AbbVie secured Venclexta’s approval in 2018 on the basis of an 80-patient trial with no comparison to placebo treatment. The companies, therefore, needed to run more trials to confirm its benefit.

The only targeted agent approved for first-line AML treatment, Venclexta was tested in combination with azacitadine against azacitadine alone in 431 patients who didn’t qualify for intensive induction chemotherapy, similar to its authorized use. The companies hoped to show that patients on the combination lived longer and were more likely to go into remission.

Roche’s Monday statement said VIALE-A achieved those goals, but did not disclose any specific data. Patients with AML have a five-year survival rate of less than 5% — similar to advanced lung cancer — and 38,000 new patients are diagnosed each year in the United States and Europe, according to the company.

Last month, the VIALE-C trial showed the cytarabine combination reduced the risk of death by 25%, a result that missed statistical significance. That finding raised questions similar trials could fail and push the FDA to pull its AML approval. The companies’ announcement Monday, however, should ease those worries.

​Venclexta is a fast-growing product for the two companies, with AbbVie reporting revenue from its share of the collaboration more than doubled to $792 million in 2019. Another key Phase 3 readout is due soon, testing the drug in multiple myeloma in combination with Pomalyst and dexamethasone in relapsed disease.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40